[Risk factors for hematologic toxicity and multifaceted analysis of blood in Hodgkin's disease: a model for hematologic toxicity].
Vopr Onkol 56(5):571-5 (2010) PMID 21137237
Basic hematological features of CEA/ABVD medication for Hodgkin's disease were studied. An effective model was worked out on the principle of data discrimination for predicting different leukocytic toxicities induced by cytostatics-1 administration, once in two weeks. It might predict individual limits (dosage and intervals) of a chemotherapy course unless a colony-stimulation technique is used.
Version: za2963e q8za6 q8zb1 q8zc2 q8zd0 q8ze0 q8zf2 q8zg2